Agenus Inc. clinical trials
Also known as Antigenics.
The registry lists 40 studies whose lead sponsor is Agenus Inc. or one of 2 companies grouped under it. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Nov 5, 2026.
Our grouping of 3 registry names, not the registry’s. See them and correct one ↓
- 40studies on the registry
- 0open to participants now
- 1reach primary completion within a year
What it is testing
The drugs Agenus Inc.’s studies test, most studies first; none is open now — 8 drugs with a page of their own. Each count opens the studies in search.
Studies, none open
Coming up
1 of Agenus Inc.’s studies under way reach primary completion within a year. The dates are the sponsor’s own estimates, which often move.
Phase 3 Other phases
- NNov ’26’26
- DDec
- JJan ’27’27
- FFeb
- MMar
- AApr
- MMay
- JJun
- JJul
- AAug
- 1SSep
- OOct
- NNov
The study
Add it to your calendar (.ics) → With an account.
What changed recently
From the registry's own updates since Oct 19, 2026.
Stopped1
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedOct 19, 2026NCT05529316
All 40 at a glance
Where each study is in its life, its phase and its countries. Each count opens them in search.
Over the years
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 519
- 20
- 21
- 22
- 23
- 24
- 25
- 026
By the year each study started; 10 started before 2010. 2026 so far in the lighter column.
Registry sponsor names on this page
Our grouping. This page groups the registry's lead sponsor names by company — our grouping, not the registry's. It can be wrong or incomplete: an acquired company whose name never mentions its owner may be missing. Use “Something wrong?” under any name below to correct it.
Tell us about a missing company
Each name exactly as ClinicalTrials.gov lists it, and how it relates to Agenus Inc.
- Agenus Inc.31 studiesSame company
Something wrong?
- Aronex Pharmaceuticals6 studies →Acquired — became part of Agenus Inc., Jul 12, 2001 · source ↗
Something wrong?
- MiNK Therapeutics3 studies →Divested — left Agenus Inc., Jul 17, 2025 · 1 more first submitted after it left, not counted · source ↗
Something wrong?
Studies
Recruiting first, then most recently updated. Showing 40 of 40.
- Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)AvailableNCT05572970
- Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory ApprovalAvailableNCT06751524
- A Study of Botensilimab and Balstilimab for the Treatment of Colorectal CancerActive, not recruitingNCT05608044Phase 2
- A Study of Botensilimab (AGEN1181) for the Treatment of Advanced MelanomaTerminatedNCT05529316Phase 2
- A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)CompletedNCT03495882Phase 1/2
- A Study of Botensilimab in Participants With Metastatic Pancreatic CancerCompletedNCT05630183Phase 2
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerActive, not recruitingNCT03860272Phase 1
- RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical CancerTerminatedNCT03894215Phase 2
- A Clinical Trial to Evaluate the Safety of agenT-797 in COVID-19 Participants With ARDSCompletedNCT04582201Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- A Study Investigating AGEN1777 in Participants With Advanced Solid TumorsCompletedNCT05025085Phase 1
- A Study of AGEN2034 in Advanced Tumors and Cervical CancerCompletedNCT03104699Phase 1/2
- Study of AGEN1571 in Participants With Advanced Solid TumorsCompletedNCT05377528Phase 1
- AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent TherapyCompletedNCT02694822Phase 1/2
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerCompletedNCT04121676Phase 1
- A Study Investigating agenT-797 in Participants With Relapsed/Refractory Solid TumorsCompletedNCT05108623Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical CancerWithdrawnNCT05033132Phase 2
- A Safety and Effectiveness Study of Vaccine Therapy in Patients With Indolent LymphomaCompletedNCT00081809Phase 2
- agenT-797 in Participants With Relapsed/Refractory Multiple MyelomaCompletedNCT04754100Phase 1
Sponsor listed in the registry: MiNK Therapeutics · First submitted before MiNK Therapeutics left Agenus Inc.
- Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)WithdrawnNCT04943627Phase 3
- A Study in Subjects With Advanced Solid TumorsTerminatedNCT04156100Phase 1
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaWithdrawnNCT04607200Phase 2
- Phase 1a Study to Evaluate Immunogenicity of ASV®CompletedNCT03673020Phase 1
- Biological Efficacy Study of HerpV Vaccine With QS-21 to Treat Participants With Recurrent Genital HerpesCompletedNCT01687595Phase 2
- Study of Vitespen (HSPPC-96, Oncophage ®) for Immune Response Assessment in Participants With Resectable Renal Cell Carcinoma at Intermediate Risk of RecurrenceTerminatedNCT01147536Phase 2
- Study of AGEN1884 With Pembrolizumab in 1L NSCLCTerminatedNCT03411473Phase 2
- Safety and Tolerability Study of AutoSynVax™ Vaccine in Subjects With Advanced CancerTerminatedNCT02992977Phase 1
- Antifungal Therapy for Fever and Neutropenia in Patients Receiving Treatment for Hematologic CancerCompletedNCT00002742Phase 3
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted before Aronex Pharmaceuticals became part of Agenus Inc.
- Survival Study Of Oncophage® vs. Observation In Patients With Kidney CancerCompletedNCT00033904Phase 3
- Study of Heat Shock Protein-Peptide Complex (HSPPC-96) Versus IL-2/DTIC for Stage IV MelanomaCompletedNCT00039000Phase 3
- Trial to Compare the Routes of Administration of an Investigational, Personalized, Therapeutic Cancer Vaccine Oncophage (HSPPC-96) in Patients With Metastatic Renal Cell CarcinomaTerminatedNCT00082459Phase 2
- AG-858 in Patients Who Are Cytogenetically Positive After Treatment With Gleevec™TerminatedNCT00058747Phase 2
- Clinical Trial Studying a Personalized Cancer Vaccine in Patients With Non-metastatic Kidney CancerTerminatedNCT00126178Phase 3
- Study of the Feasibility to Derive Vaccine From Tumor Tissue in Patients With Non-Small Cell Lung CancerCompletedNCT00098085Phase 2
- Trial Evaluating Safety, Tolerability and Immune Response of AG-707CompletedNCT00231049Phase 1
- Study of L-NDDP (Aroplatin) in Patients With Advanced Solid Malignancies or B-Cell LymphomaCompletedNCT00316511Phase 1
- Aroplatin and Capecitabine in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00081536Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- Aroplatin and Gemcitabine in Patients With Advanced Pancreatic Cancer Resistant to Standard TherapiesStatus unknownNCT00081549Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Solid MalignanciesStatus unknownNCT00057395Phase 1/2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- A Safety and Effectiveness Study of Aroplatin in Patients With Advanced Colorectal Cancer Resistant to Standard TherapiesStatus unknownNCT00043199Phase 2
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted after Aronex Pharmaceuticals became part of Agenus Inc.
- Safety and Effectiveness of Zintevir (AR177) Given to HIV-Infected PatientsCompletedNCT00002403Phase 1
Sponsor listed in the registry: Aronex Pharmaceuticals · First submitted before Aronex Pharmaceuticals became part of Agenus Inc.